Ayala Pharmaceuticals Inc (ADXS)

[mpreorder]

I came across this on Medpage Today - what caught my attention is this paragraph:

"The results compare favorably with those seen with bevacizumab (Avastin) in GOG-227C (12-month survival of 30%), which subsequently gained regulatory approval in first-line combination with chemotherapy," he added. "This is significant given that about half of the patients in [the current trial] had received prior bevacizumab."

This is certainly something that oncologists will consider when treating cervical cancer. Even in the unlikely event that response rates can be described as similar, there is a signal that a subset of patients will respond to Axal and not to Avastin. Or will respond to Axal after Avastin fails. So it would only make sense to start with Axal rather than Avastin.